<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770952</url>
  </required_header>
  <id_info>
    <org_study_id>ATS K020</org_study_id>
    <secondary_id>2006-002271-41</secondary_id>
    <secondary_id>D-PIO-112</secondary_id>
    <secondary_id>U1111-1114-3221</secondary_id>
    <nct_id>NCT00770952</nct_id>
  </id_info>
  <brief_title>Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.</brief_title>
  <official_title>Effects of Pioglitazone in Combination With Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and&#xD;
      glimepiride combination therapy compared to glimepiride monotherapy in subjects with Type 2&#xD;
      Diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tight glycemic control is mandatory for the prevention and treatment of vascular&#xD;
      complications in patients suffering from diabetes mellitus. After onset of Type 2 Diabetes,&#xD;
      patients are usually treated with diet along with or without different combinations of oral&#xD;
      drugs. One first-line drug class are sulfonylurea drugs that are preferably provided to&#xD;
      patients who are not obese. The mode of action of sulfonylurea drugs is to increase beta-cell&#xD;
      secretion, but it could be shown that they lead to deterioration of the beta-cell secretion&#xD;
      product over time, resulting in increased proinsulin secretion. Since proinsulin is an&#xD;
      independent cardiovascular risk factor, recent publications have demonstrated an increased&#xD;
      risk for cardiovascular events in patients treated with sulfonylurea drugs as compared to&#xD;
      other treatment methods.&#xD;
&#xD;
      Combination therapy of sulfonylurea drugs with glitazones has been shown to counterbalance&#xD;
      the effect of deteriorated beta-cell secretion and to improve insulin sensitivity and the&#xD;
      levels of proinsulin, C-peptide and other laboratory surrogate markers for cardiovascular&#xD;
      risk. Proving that the treatment of diabetic patients with higher doses of beta cytotropic&#xD;
      agents can be avoided and beta-cell function can be preserved by using pioglitazone in&#xD;
      combination with low dose sulfonylurea drugs, it will be possible to optimize the treatment&#xD;
      of patients with type 2 diabetes who are not controlled efficiently by sulfonylurea drugs&#xD;
      monotherapy.&#xD;
&#xD;
      In this study patients will be enrolled who are inefficiently treated with a Glimepiride&#xD;
      monotherapy. Patients will be either randomized to a combinational therapy of Pioglitazone&#xD;
      and Glimepiride or Glimepiride monotherapy. If possible, study medication will be up-titrated&#xD;
      to maximal dosage levels in both treatment arms to observe maximal and comparable treatment&#xD;
      effects. Stable effects on beta-cell function will be observed after 24 weeks of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Homeostatic Model Assessment - Beta cell.</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glycosylated Hemoglobin.</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in oral glucose tolerance testing.</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Insulin.</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Proinsulin.</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in C-peptide.</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in High sensitivity C-Reactive Protein.</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Adiponectin.</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Homeostatic Model Assessment - Sensitivity.</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Triglycerides</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Low Density Lipoprotein-Cholesterol</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in High Density Lipoprotein-Cholesterol</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total Cholesterol</measure>
    <time_frame>Week: 24 or Final Visit beyond week 12.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride 4 mg to 6 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone and Glimepiride</intervention_name>
    <description>Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:&#xD;
Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:&#xD;
Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks.</description>
    <arm_group_label>Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD</arm_group_label>
    <other_name>ACTOSÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:&#xD;
Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:&#xD;
Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks.</description>
    <arm_group_label>Glimepiride 4 mg to 6 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes according to the American Diabetes Association Criteria.&#xD;
&#xD;
          -  Treatment with Glimepiride monotherapy (1-3 mg per day) 3 months before entering the&#xD;
             study.&#xD;
&#xD;
          -  Glycosylated hemoglobin greater than 6.5%, but less than 8.5% and/ or fasting plasma&#xD;
             glucose greater than 7 mmol/l within the last 4 weeks.&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active must agree to use adequate&#xD;
             contraception, and can neither be pregnant nor lactating from Screening throughout the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 Diabetes mellitus.&#xD;
&#xD;
          -  History of hypersensitivity to the study drugs or to drugs with similar chemical&#xD;
             structures.&#xD;
&#xD;
          -  Progressive fatal disease.&#xD;
&#xD;
          -  History of drug or alcohol abuse during the last 5 years.&#xD;
&#xD;
          -  More than one unexplained episode of severe hypoglycemia within 6 months prior to&#xD;
             entering the study.&#xD;
&#xD;
          -  A history of significant cardiovascular (New York Heart Association stage I - IV),&#xD;
             respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5&#xD;
             times the upper limit of the normal reference range), renal (serum creatinine greater&#xD;
             than 1.8 mg/dl; glomerular filtration rate less than 40 ml/min as estimated by the&#xD;
             Cockroft-Gault formula), neurological, psychiatric and/or hematological disease,&#xD;
             history of macular edema.&#xD;
&#xD;
          -  Blood donation within the last 30 days.&#xD;
&#xD;
          -  Is required to take or intends to continue taking any disallowed medication, any&#xD;
             prescription medication, herbal treatment or over-the counter medication that may&#xD;
             interfere with evaluation of the study medication, including:&#xD;
&#xD;
               -  CYP2C9 inductors&#xD;
&#xD;
               -  CYP2C9 inhibitors&#xD;
&#xD;
               -  rifampicin&#xD;
&#xD;
               -  fluconazole&#xD;
&#xD;
               -  drugs used for treating type 2 diabetes (insulin, insulin analogous compounds and&#xD;
                  oral antidiabetic drugs)&#xD;
&#xD;
          -  Pretreatment with thiazolidinediones within the last 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Adviser Clinical Research</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Pharma Gmbh, Aachen (Germany)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-WÃ¼rttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ingolstadt</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frielendorf</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotenburg</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siegen</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kallstadt</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mayen</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuwied</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rhaunen</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Friedrichsthal</city>
        <state>Saarland</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>MeiÃen</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&amp;fileTypeCode=ACTOSPI</url>
    <description>ACTOSÂ® Package Insert</description>
  </link>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <last_update_submitted>July 1, 2010</last_update_submitted>
  <last_update_submitted_qc>July 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Takeda Pharma GmbH, Aachen (Germany)</organization>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus, Lipoatrophic</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

